The SCOPE Study: Health-Care Consumption Related to Patients with Chronic Obstructive Pulmonary Disease in France

Detournay, B.; Pribil, C.; Fournier, Michel; Housset, B.; Huchon, G.; Huas, Dominique; Godard, P.; Voinet, C.; Chanal, I.; Jourdanne, C.; Durand‐Zaleski, Isabelle

doi:10.1111/j.1524-4733.2004.72329.x

Cited by 55 publications

(37 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This implies that still other factors yet unknown play a role. Previous cost of illness studies including prediction analysis, also in other CFS patient populations, has until now scarcely explained more than a quarter of the total variance in health care use [2,[28][29][30][31].…”

Section: Discussionmentioning

confidence: 99%

Determinants of health care use in chronic fatigue syndrome patients: A cross-sectional study

Scheeres

Wensing

Severens

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Determinants of health care use in chronic fatigue syndrome patients: A cross-sectional study

Scheeres

Wensing

Severens

et al. 2008

Journal of Psychosomatic Research

View full text Add to dashboard Cite

“…41% of this cost was directly related to medical care and follow-up of the patient, 25% to medical care of exacerbations, and 34% to other associated disorders. 33% of the cost was related to hospitalisation and 31% directly to prescriptions for medication [24]. In Europe, the annual cost per patient varies from J151 to J3,912 [25].…”

Section: Impact Of Copd On Morbiditymentioning

confidence: 99%

Epidemiology of COPD

Rahérison¹,

Girodet²

2009

European Respiratory Review

410

281

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is responsible for early mortality, high death rates and significant cost to health systems. The projection for 2020 indicates that COPD will be the third leading cause of death worldwide (from sixth in 1990) and fifth leading cause of years lost through early mortality or handicap (disability-adjusted life years) (12th in 1990). Active smoking remains the main risk factor, but other factors are becoming better known, such as occupational factors, infections and the role of air pollution. Prevalence of COPD varies according to country, age and sex. This disease is also associated with significant comorbidities. COPD is a disorder that includes various phenotypes, the continuum of which remains under debate. The major challenge in the coming years will be to prevent onset of smoking along with early detection of the disease in the general population.

show abstract

“…Average total medical resource consumption of a COPD patient per year was estimated at J4,366 by the French SCOPE (SoCiO-Pharmaco-Economique de la BPCO en France) study [85]. Of this cost, 41% was directly related to COPD follow-up, 25% to COPD-related complications (mainly exacerbations) and 34% to other diseases.…”

Section: Economic Burdenmentioning

confidence: 99%

Definition, epidemiology and natural history of COPD

Viegi¹,

Pistelli²,

Sherrill³

et al. 2007

European Respiratory Journal

352

268

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the fifth cause of morbidity and mortality in the developed world and represents a substantial economic and social burden. Patients experience a progressive deterioration up to end-stage COPD, characterised by very severe airflow limitation, severely limited and declining performance status with chronic respiratory failure, advanced age, multiple comorbidities and severe systemic manifestations/ complications.COPD is frequently underdiagnosed and under-treated. Today, COPD develops earlier in life and is less gender specific. Tobacco smoking is the major risk factor for COPD, followed by occupation and air pollution. Severe deficiency for a 1 -antitrypsin is rare; several phenotypes are being associated with elevated risk for COPD in the presence of risk factor exposure. Any patient presenting with cough, sputum production or dyspnoea should be assessed by standardised spirometry. Continued exposure to noxious agents promotes a more rapid decline in lung function and increases the risk for repeated exacerbations, eventually leading to end-stage disease.Without major efforts in prevention, there will be an increasing proportion of end-stage patients who can live longer through long-term oxygen therapy and assisted ventilation, but with elevated suffering and huge costs. Smoking prevention and smoking cessation are the most important epidemiological measurements to counteract chronic obstructive pulmonary disease epidemics.

show abstract

The SCOPE Study: Health-Care Consumption Related to Patients with Chronic Obstructive Pulmonary Disease in France

Abstract: The burden of COPD itself and its complications appeared to be of considerable magnitude in France especially for severe COPD.

Cited by 55 publications

References 12 publications

Determinants of health care use in chronic fatigue syndrome patients: A cross-sectional study

Determinants of health care use in chronic fatigue syndrome patients: A cross-sectional study

Epidemiology of COPD

Definition, epidemiology and natural history of COPD

Contact Info

Product

Resources

About